Department of Pediatrics, University of California, San Francisco, CA 94158, USA.
Departments of Pediatrics and Neurology, University of California, San Francisco, CA 94158, USA.
Brain Sci. 2015 Apr 30;5(2):165-77. doi: 10.3390/brainsci5020165.
In recent years, growth factor therapy has emerged as a potential treatment for ischemic brain injury. The efficacy of therapies that either directly introduce or stimulate local production of growth factors and their receptors in damaged brain tissue has been tested in a multitude of models for different Central Nervous System (CNS) diseases. These growth factors include erythropoietin (EPO), vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), and insulin-like growth factor (IGF-1), among others. Despite the promise shown in animal models, the particular growth factors that should be used to maximize both brain protection and repair, and the therapeutic critical period, are not well defined. We will review current pre-clinical and clinical evidence for growth factor therapies in treating different causes of brain injury, as well as issues to be addressed prior to application in humans.
近年来,生长因子治疗已成为缺血性脑损伤的一种潜在治疗方法。在多种不同的中枢神经系统 (CNS) 疾病模型中,已经测试了直接引入或刺激受损脑组织中生长因子及其受体局部产生的治疗方法的疗效。这些生长因子包括促红细胞生成素 (EPO)、血管内皮生长因子 (VEGF)、脑源性神经营养因子 (BDNF) 和胰岛素样生长因子 (IGF-1) 等。尽管在动物模型中显示出了希望,但仍未明确哪些特定的生长因子应该用于最大限度地提高脑保护和修复,并确定治疗的关键时期。我们将回顾目前在治疗不同原因的脑损伤方面生长因子治疗的临床前和临床证据,以及在应用于人类之前需要解决的问题。